Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib

被引：21
|
作者：
Nickel, Robert Sheppard [1 ]
Daves, Marla [1 ]
Keller, Frank [1 ]
机构：
[1] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷 / 11期
关键词：
IMATINIB; GROWTH; CHILDREN;
D O I：
10.1002/pbc.25551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2050 / 2051
页数：2
相关论文
共 50 条
  • [31] Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation
    Combes, Francois Pierre
    Sy, Sherwin K. B.
    Li, Ying Fei
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    CLINICAL PHARMACOKINETICS, 2024, 63 (09) : 1301 - 1312
  • [32] Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia
    Mughal, Tariq I.
    Goldman, John M.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S81 - S84
  • [33] THE COMBINATION OF PANOBINOSTAT AND PONATINIB EXERTS SYNERGISTIC CYTOTOXICITY IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA CELL LINES INCLUDING BCR-ABL GENE MUTATION WITH T315I
    Matsuda, Y.
    Yamauchi, T.
    Takai, M.
    Shigemi, H.
    Uzui, K.
    Nishi, R.
    Kimura, S.
    Maekawa, T.
    Ueda, T.
    HAEMATOLOGICA, 2014, 99 : 69 - 69
  • [34] Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case Report
    Nomura, Takuo
    Hata, Akito
    ANNALS OF VASCULAR DISEASES, 2024, 17 (01) : 51 - 54
  • [35] I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
    Gao, Congying
    Zhang, Lei
    Xu, Yun
    Ma, Xiangyu
    Chen, Peilei
    Chen, Zhe-Sheng
    Wei, Liuya
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt–autophagy pathway
    Le Yin
    Qingyang Zhang
    Sisi Xie
    Zhao Cheng
    Ruijuan Li
    Hongkai Zhu
    Qian Yu
    Huan Yuan
    Canfei Wang
    Hongling Peng
    Guangsen Zhang
    Human Cell, 2023, 36 : 1564 - 1577
  • [37] S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia
    Gupta, Pranav
    Zhang, Guannan
    Barbuti, Anna Maria
    Ding, Ke
    Pan, Jingxuan
    Druker, Brian J.
    Chen, Zhe-Sheng
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report
    Venton, Geoffroy
    Colle, Julien
    Mercier, Cedric
    Fanciullino, Raphaelle
    Ciccolini, Joseph
    Ivanov, Vadim
    Suchon, Pierre
    Sebahoun, Gerard
    Beaufils, Nathalie
    Gabert, Jean
    Hadjaj, Djamal
    Costello, Regis
    PHARMACOGENOMICS, 2015, 16 (07) : 677 - 679
  • [39] A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib
    Cea, Michele
    Cirmena, Gabriella
    Garuti, Anna
    Rocco, Ilaria
    Palermo, Claudia
    Cagnetta, Antonia
    Moran, Eva
    Colombo, Nicoletta
    Grasso, Raffaella
    Fugazza, Giuseppina
    Gobbi, Marco
    Nencioni, Alessio
    Ballestrero, Alberto
    Patrone, Franco
    LEUKEMIA RESEARCH, 2010, 34 (09) : E240 - E242
  • [40] Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy
    Isabel Moro, Maria
    Manrique, Gonzalo
    Uriarte, Rosario
    Diaz, Lilian
    LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1684 - 1686
12345